Skip to main content
. Author manuscript; available in PMC: 2024 Apr 24.
Published in final edited form as: Sci Transl Med. 2022 Sep 7;14(661):eabl8814. doi: 10.1126/scitranslmed.abl8814

Table 2.

Abandoned drug and biologic product therapies for tendon diseases (terminated in clinical development).

Phase 1 Phase 2 Phase 3/4
PDGF (becaplermin; β-tricalcium phosphate, Augment LT, Wright Medical Group) (NCT01256242) Adipose Cell Therapy (ALLO-ASC Injection, Bukwang Pharmaceuticals) (NCT03449082) Corticosteroid (Ketorolac, Kenalog) (NCT04115644)
BMP-655/ACS (bone morphogenetic protein ligand, Pfizer/Wyeth) (NCT01122498) Autologous human platelet lysate (Bharat Serums and Vaccines) (NCT01668862) NSAID (Ketprofen Topical Patch 20%) (NCT00426985)
Hypoxia-inducible factor inhibitor (daprodustat, GSK) (NCT02231190) Nitrate/nitrite (nitroglycerin) (OrthoDerm, Cure Therapeutics) (NCT00447928) NSAID [etodolac (lidocaine), Etoreat, MEDRx] (NCT01506154)
Nonbulbar dermal sheath cells (RCT-01, RepliCel Life Sciences) (NCT02330146) NSAID [ketoprofen (transdermal patch), Endo Health Solutions] (NCT00426985)